文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

阿法替尼与厄洛替尼二线治疗晚期肺鳞癌的成本效果分析。

Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.

机构信息

Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, PR China.

Department of Thoracic Surgery, General Hospital of Ningxia Medical University, Ningxia, PR China.

出版信息

Future Oncol. 2018 Nov;14(27):2833-2840. doi: 10.2217/fon-2018-0321. Epub 2018 Jun 7.

DOI:10.2217/fon-2018-0321
PMID:29878848
Abstract

AIM: To investigate the cost-effectiveness of afatinib and erlotinib as second-line therapy for advanced squamous cell carcinoma of the lung. MATERIALS & METHODS: A decision-analytic model was developed for projecting the economic outcomes. Clinical parameters and utilities were from the LUX-Lung 8 trial. Costs were mainly estimated from the Chinese health system. The outcome was the incremental cost-effectiveness ratio. RESULTS: The afatinib strategy generated additional 0.154 quality-adjusted life-years compared with erlotinib, with incremental costs of ¥16,852. Relative to erlotinib, afatinib resulted in an incremental cost-effectiveness ratio of ¥109,429 per quality-adjusted life-year gained. The overall survival time of afatinib had a considerable impact on the model outcomes. CONCLUSION: Afatinib is a cost-effective treatment option compared with erlotinib in patients with squamous cell carcinoma.

摘要

目的：研究阿法替尼与厄洛替尼作为二线治疗晚期肺鳞癌的成本效果。 材料与方法：建立决策分析模型以预测经济结果。临床参数和效用值来自 LUX-Lung 8 试验。成本主要来自中国的医疗体系。结果为增量成本效果比。 结果：与厄洛替尼相比，阿法替尼方案产生了额外的 0.154 个质量调整生命年，增量成本为 16852 元。与厄洛替尼相比，阿法替尼的增量成本效果比为每获得一个质量调整生命年增加 109429 元。阿法替尼的总生存时间对模型结果有较大影响。 结论：与厄洛替尼相比，阿法替尼是一种具有成本效果的治疗选择，适用于肺鳞癌患者。

相似文献

[1]
Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.

Future Oncol. 2018-6-7

[2]
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.

Lung Cancer. 2018-11-24

[3]
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.

Value Health. 2015-9

[4]
Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.

Future Oncol. 2018-10-15

[5]
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

Clin Lung Cancer. 2017-6-23

[6]
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Health Technol Assess. 2015-6

[7]
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

Lancet Oncol. 2015-7-5

[8]
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.

PLoS One. 2020-4-8

[9]
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.

Expert Opin Pharmacother. 2018-11-3

[10]
Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Lung Cancer. 2017-7

引用本文的文献

[1]
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.

Strahlenther Onkol. 2024-9

[2]
Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review.

BMJ Glob Health. 2023-11-29

[3]
First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.

Orphanet J Rare Dis. 2023-10-16

[4]
A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China.

BMC Health Serv Res. 2023-7-19

[5]
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.

Front Pharmacol. 2022-10-26

[6]
First-line nivolumab plus ipilimumab or chemotherapy chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis.

Ther Adv Med Oncol. 2022-9-16

[7]
Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.

J Manag Care Spec Pharm. 2022-4

[8]
Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma.

Ther Adv Med Oncol. 2022-1-22

[9]
Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life.

J Healthc Eng. 2021

[10]
Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.

Front Oncol. 2021-4-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索